Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Richter-Helm BioLogics, a biotechnology company, and Athera Biotechnologies, an atherosclerosis R&D company, have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium.
Subscribe to our email newsletter
This agreement secures a cost efficient long-term development and manufacturing plan for Athera, including possible future large volume commercial production.
Annexin A5 is a biotechnology product produced using Richter-Helm’s E coli based expression system. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 litre production scale.
The recombinant protein Annexin A5 is intended for the treatment of patients with acute coronary syndrome and who are at imminent risk for myocardial infarction.
Bert Behnke, managing director of Richter-Helm, said: “The Annexin A5 project fits well with the competence and experience of our company. We are confident that our collaboration will be as efficient and constructive as our negotiations were.”